9 withdrawn. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Withdrawn 9 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus | Phase 1 | Withdrawn | Genentech, Inc. | 2026-06-30 | 2026-08-05 | |
| A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc) TAK-007, Chemotherapy Agents - Refractory Lupus Nephritis, Refractory Systemic Sclerosis | Phase 1 | Withdrawn | Takeda | 2025-06-13 | 2025-04-06 | |
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus ATA3219 - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Withdrawn | Atara Biotherapeutics | 2025-04-16 | 2025-04-24 | |
| A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) IMPT-514 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Withdrawn | Lyell Immunopharma, Inc. | 2024-02-15 | 2025-02-10 | |
| TP10 Use in Patients With C3 Glomerulopathy (C3G) TP10 - Dense Deposit Disease | Phase 1 | Withdrawn | University of Iowa | 2014-11-01 | 2016-10-27 | |
| Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 Galactose - Focal Segmental Glomerulosclerosis | Phase 1 | Withdrawn | Northwell Health | 2008-12-01 | 2015-09-07 | |
| Sulodexide Treatment in Patients With Dense Deposit Disease Sulodexide - Dense Deposit Disease | Phase 1 | Withdrawn | University of Iowa | 2007-12-01 | 2015-06-11 |
Lupus Nephritis (6) · Lupus Erythematosus, Systemic (5) · Glomerulonephritis, Membranoproliferative (2) · Autoimmune Diseases (1) · Epstein-Barr Virus Infections (1) · Glomerulosclerosis, Focal Segmental (1) · Scleroderma, Systemic (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Glomerulonephritis (9) · Kidney Diseases (9) · Male Urogenital Diseases (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Immune System Diseases (8) · Connective Tissue Diseases (6) · Skin and Connective Tissue Diseases (6) · Autoimmune Diseases (5) · DNA Virus Infections (1) · Herpesviridae Infections (1) · Infections (1)
Cyclophosphamide (1) · Galactose (1) · fludarabine (1) · glucuronyl glucosamine glycan sulfate (1)
University of Iowa (2) · AbelZeta Inc. (1) · Atara Biotherapeutics (1) · Caribou Biosciences, Inc. (1) · Genentech, Inc. (1) · Lyell Immunopharma, Inc. (1) · Northwell Health (1) · Takeda (1)
United States (8) · Australia (1)
Richard JH Smith, MD (2) · Howard Trachtman, MD (1) · Janal Urich (1) · Scott Antonia (1)